What Are Non-Stimulant ADHD Medications and How Do They Work?

Non-stimulant ADHD medications are prescription drugs that treat ADHD without amphetamine or methylphenidate. Four have FDA approval for ADHD: atomoxetine (Strattera), viloxazine (Qelbree), extended-release guanfacine (Intuniv) and extended-release clonidine. The labels for Strattera, Intuniv and extended-release clonidine each state that the drug is not a controlled substance, which is the main practical difference from stimulants such as Adderall and Vyvanse.

Non-stimulants are often described as the weaker choice, but the gap depends on which stimulant you compare them with. A 2018 analysis in The Lancet Psychiatry pooled 133 double-blind trials and found that, in adults, atomoxetine improved core ADHD symptoms by about as much as methylphenidate (effect sizes of 0.45 and 0.49 against placebo), while amphetamines did more (0.79). This post covers which non-stimulants are approved, how they work, how they compare, and what to ask a prescriber.

This article is for general education and is not medical advice. Talk with your prescriber before starting, stopping or changing any medication.

What Counts as a Non-Stimulant ADHD Medication?

A non-stimulant ADHD medication is any ADHD treatment that is not a central nervous system stimulant. Stimulants fall into two families: amphetamines and methylphenidate. Everything else used for ADHD sits in the non-stimulant group.

The legal status is different too. The FDA labels for Vyvanse and Adderall XR identify both as Schedule II controlled substances and carry a boxed warning about abuse, misuse, and addiction. The Strattera label states that atomoxetine "is not a controlled substance," and the Intuniv label says guanfacine "has no known potential for abuse or dependence."

That difference affects refills, pharmacy rules and telehealth prescribing, which is why non-stimulants come up so often in conversations about ADHD medication through telepsychiatry.

Which Non-Stimulants Are FDA Approved, and for What Ages?

Four non-stimulants carry an FDA indication for ADHD. Two of them are approved for adults.

• Atomoxetine (Strattera): the label covers ADHD in adults and in children 6 years and older.

• Viloxazine (Qelbree): first approved in the United States in 2021. The label was revised in April 2022 and covers adults and children 6 years and older.

• Guanfacine extended-release (Intuniv): approved for ADHD alone or added to a stimulant. Its effectiveness was studied in children and adolescents ages 6 to 17.

• Clonidine extended-release: approved for ADHD alone or added to a stimulant. It was also studied in ages 6 to 17.

Adults are sometimes prescribed guanfacine or clonidine for ADHD anyway. That is off-label use, which means a prescriber is using an approved drug for a group or purpose the label does not list. If it is suggested for you, ask what evidence supports the choice in your case.

Other drugs, including the antidepressant bupropion, have been studied for ADHD. Bupropion appeared in The Lancet Psychiatry analysis with an effect size of 0.46 in adults.

How Do Non-Stimulants Work Differently From Stimulants?

Stimulants and non-stimulants act on some of the same brain chemicals in different ways. The Vyvanse label explains that amphetamines block the reuptake of norepinephrine and dopamine and increase their release.

Atomoxetine is described on its label as a selective norepinephrine reuptake inhibitor. It keeps norepinephrine available longer without the direct dopamine release that stimulants cause.

Guanfacine and clonidine belong to a different class. The Intuniv label calls guanfacine a central alpha 2A adrenergic receptor agonist, and extended-release clonidine is labeled a centrally acting alpha 2 adrenergic agonist. Both can lower blood pressure, which explains some of their side effects.

Because the mechanisms differ, the experience differs. Ask your prescriber how long a specific medication should be given before you judge whether it is working, since that answer is not the same for every drug.

How Well Do Non-Stimulants Work Compared With Stimulants?

The largest comparison to date favors stimulants as the first choice. The Lancet Psychiatry analysis by Cortese and colleagues included 8,131 adults in its main efficacy comparison. Amphetamines outperformed atomoxetine and methylphenidate in head-to-head comparisons for both children and adults. The authors concluded that the evidence supports methylphenidate for children and adolescents and amphetamines for adults as first-choice medications for short-term treatment.

Two details in that analysis matter for anyone considering a non-stimulant. Atomoxetine still beat placebo in adults by a margin close to methylphenidate. And the researchers did not find enough data to compare the drugs at 26 or 52 weeks, so the long-term picture is less certain for every option.

Averages also hide individual results. A medication with a smaller average effect can still be the one that works for you, and a stronger one can be the one you cannot tolerate. That is the purpose of ADHD medication management: adjusting the plan to the person instead of the study average.

What Side Effects and Warnings Should You Know About?

Each non-stimulant has its own profile, and the FDA labels list the reactions seen most often in trials.

• Viloxazine in adults: insomnia, headache, sleepiness, fatigue, nausea, decreased appetite, dry mouth and constipation.

• Atomoxetine in children: nausea, vomiting, fatigue, decreased appetite, abdominal pain and sleepiness.

• Guanfacine extended-release: low blood pressure, sleepiness, fatigue, nausea and lethargy.

• Clonidine extended-release: sleepiness, fatigue, irritability, insomnia, nightmares, constipation and dry mouth.

Strattera and Qelbree both carry a boxed warning about suicidal thoughts and behaviors. The Strattera warning applies to pediatric patients and calls for close monitoring, especially in the first months of treatment and when the dose changes. Tell your prescriber right away about new or worsening mood changes on any ADHD medication.

Non-stimulants are not free of trade-offs. In The Lancet Psychiatry analysis, the odds of stopping treatment because of side effects were more than double those of placebo for adults taking atomoxetine. The same was true of methylphenidate, and the odds were higher still for amphetamines. A fuller list of what to watch for is in the post on side effects of ADHD medications.

Who Might Be Prescribed a Non-Stimulant?

A prescriber may suggest a non-stimulant when a stimulant has not helped enough, when side effects were a problem, or when a controlled substance is not a good fit. The stimulant labels direct prescribers to assess each patient's risk for abuse, misuse and addiction before prescribing, and that assessment sometimes points toward a non-stimulant.

Supply is another reason. A CDC report published in October 2024 found that about one third of adults with ADHD took a stimulant in the prior year, and 71.5% of them had trouble getting a prescription filled because the medication was not available. Only 5.9% of adults with ADHD reported taking a non-stimulant.

Guanfacine and clonidine can also be added to a stimulant. Both labels include use "as adjunctive therapy to stimulant medications."

The right choice starts with an accurate diagnosis. If you have not had a full assessment, the post on how ADHD is diagnosed and treated in adults explains what that involves.

FAQ

Are non-stimulant ADHD medications controlled substances?

The labels for Strattera, Intuniv and extended-release clonidine state that they are not controlled substances. Stimulants such as Vyvanse and Adderall XR are Schedule II controlled substances.

Which non-stimulants are approved for adults with ADHD?

Atomoxetine (Strattera) and viloxazine (Qelbree) have FDA labels that include adults. Extended-release guanfacine and clonidine were studied in ages 6 to 17, so adult use is off-label.

Do non-stimulants work as well as Adderall?

On average, no. In a 2018 analysis of 133 trials, amphetamines had a larger effect in adults (0.79) than atomoxetine (0.45). Individual responses vary, and some people do better on a non-stimulant.

Can a non-stimulant be taken with a stimulant?

Extended-release guanfacine and extended-release clonidine are both FDA approved as add-on therapy to stimulant medications. Whether a combination makes sense for you is a decision for your prescriber.

Can non-stimulants be prescribed through telehealth?

Federal in-person exam rules for telehealth apply to controlled substances. Medications that are not controlled substances fall outside those rules, though state law and a prescriber's own judgment still apply.

Is it safe to stop a non-stimulant suddenly?

Do not stop any ADHD medication without talking to your prescriber. Guanfacine and clonidine affect blood pressure, and the Intuniv label lists rebound hypertension among its warnings.

ADHD Medication Management in Greensburg, PA

T and C Psychiatric Services LLC is based in Greensburg, PA. Its board-certified nurse practitioners provide psychiatric evaluations and medication management for ADHD, with regular follow-ups to check whether a medication is working and adjust treatment as needed. Appointments are available in person and through online and remote services.

If you or someone you know is in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline, text HOME to 741741 to reach the Crisis Text Line, or call 911 for an immediate emergency.

Visit T and C Psychiatric Services or call 724-951-2413 today. Contact us for more information.